BPC 157 is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a protein found in human gastric juice. It is investigated in cell culture and rodent models for its effects on angiogenesis, tendon fibroblast behaviour and gastrointestinal tissue repair. A formal BPC 157 side effects profile has not been established, because the peptide has not completed the controlled human clinical trials that would define one. What exists is a body of preclinical literature, mostly from a single research group, in which adverse observations are rarely the primary endpoint. This article summarises what that literature reports and where its gaps lie, and sets out the handling requirements for laboratory use.
What is BPC 157?
BPC 157 takes its name from “Body Protection Compound”. It is a partial sequence of a larger protein, BPC, first isolated from human gastric juice. The fragment contains 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular formula is C62H98N16O22 and its molecular weight is approximately 1419.5 g/mol. The high proline content gives the molecule a relatively rigid backbone and is thought to contribute to its unusual stability in gastric fluid compared with many short peptides.
The compound was characterised principally by a research group at the University of Zagreb, Croatia, led by Predrag Sikirić, from the early 1990s onward. The group studied it first in models of gastric and intestinal injury and later in musculoskeletal, vascular and neurological models. The peptide is sometimes written as BPC-157, BPC157 or, in older literature, PL 14736 or Bepecin. Its classification matters for any discussion of safety. BPC 157 is not a licensed medicinal product in the United Kingdom, it has no marketing authorisation from the MHRA, and it is listed as a non-approved substance under the World Anti-Doping Agency prohibited list. For laboratory purposes it is a research peptide, sold as a lyophilised powder.
Mechanism of action
The mechanism of BPC 157 has not been fully resolved, and the published explanations remain largely hypotheses based on cell and animal work. The most frequently reported finding concerns the vascular endothelial growth factor receptor 2 (VEGFR2) pathway. In cultured endothelial cells, the peptide has been reported to increase VEGFR2 expression and to activate downstream signalling through the Akt and eNOS axis. This is relevant to the angiogenic effects observed in animal tissue models, including increased formation of new vessels in ischaemia and wound models.
A second reported pathway involves the growth hormone receptor. In cultured tendon fibroblasts, BPC 157 exposure was associated with increased growth hormone receptor expression and with activation of the JAK2 signalling cascade, which in turn was linked to enhanced fibroblast proliferation in vitro. A third area of study concerns the nitric oxide system. Several rodent studies describe modulation of nitric oxide synthesis and of the balance between NOS inhibition and NO precursor effects, although the interpretation is debated.
Other proposed actions include interaction with the FAK-paxillin pathway in tendon cell migration, effects on the dopaminergic and serotonergic systems in rodent behavioural models, and an influence on the expression of early growth response genes. No single high-affinity receptor for BPC 157 has been definitively identified. This is one reason the safety question is difficult. A compound acting through several overlapping signalling pathways, notably those governing angiogenesis and cell proliferation, requires careful long-term toxicological evaluation, and that evaluation has not been performed to a regulatory standard. Researchers working with the peptide should treat the mechanistic literature as provisional.
What the research shows
The available literature is heavily weighted toward rodent studies, and a large proportion originates from the same group. Independent replication is limited, which is itself an important caveat for anyone interpreting the safety record. Four research areas are summarised below.
The first concerns tendon healing. Studies from the Zagreb group examined transected rat Achilles tendon and reported that peptide administration was associated with improved histological and functional measures compared with controls. Subsequent work by Chang and colleagues examined tendon fibroblasts in culture and described effects on outgrowth, survival and migration, as well as the growth hormone receptor findings mentioned above. These papers can be located through PubMed, where the tendon fibroblast work is indexed. In the rodent studies, administration was generally by intraperitoneal or topical routes at microgram- and nanogram-per-kilogram quantities, and the authors did not highlight adverse findings.
The second area concerns angiogenesis. Work on endothelial cells and on rodent hindlimb ischaemia models reported VEGFR2 pathway activation and increased vessel formation. A key observation for safety discussions is that pro-angiogenic activity is, in theory, a consideration in any context where abnormal vessel growth is a concern, such as tumour biology. The published BPC 157 literature includes some reports describing no tumour-promoting effects in the models examined, but those studies are not substitutes for formal carcinogenicity testing. The relevant papers are indexed on PubMed.
The third area concerns gastrointestinal models. This is the oldest research stream, and it includes rat models of gastric lesions, inflammatory bowel injury and anastomosis healing. Reported observations were largely about tissue integrity rather than adverse events.
The fourth is the limited human literature. A small number of preliminary clinical reports exist, including retrospective and pilot-scale reports in musculoskeletal and urological contexts, and a small pilot safety report on intravenous administration. These involve very few participants, lack the controls and statistical power of registered trials, and cannot be treated as establishing a safety profile. A phase I programme for a related oral formulation was reportedly initiated in the early 2000s, but complete results were never published in the peer-reviewed literature.
Taken together, the preclinical record contains few reports of overt toxicity at the doses studied, but the absence of reported adverse effects is not the same as evidence of safety. Studies were generally short, used small groups and were not designed to detect rare, delayed or cumulative effects.
Why a defined side effect profile does not exist
Several structural gaps explain why the phrase “BPC 157 side effects” cannot currently be answered with a list. First, there is no completed set of regulatory toxicology studies in the public domain, such as repeat-dose toxicity across species, genotoxicity, reproductive toxicity or carcinogenicity assessments. Second, there are no large randomised controlled trials in humans. Third, pharmacokinetic data are sparse, so exposure in different tissues cannot be characterised reliably. Fourth, most studies come from a single laboratory network, so independent confirmation is limited.
There is also a quality-related dimension. Where adverse reactions have been discussed in non-peer-reviewed settings, the compound consumed is often of unknown identity and purity. Impurities in synthetic peptides, such as truncated sequences, deletion peptides, residual solvents and counter-ion content, are plausible contributors to unexpected biological effects. This is a documented issue across the research-peptide market, and it is the main reason analytical verification is treated as a core requirement rather than an optional extra. Researchers designing in-vitro or animal experiments should attribute unexpected observations to the compound only after excluding contamination, endotoxin and formulation artefacts.
Research applications
In the laboratory, BPC 157 is used as a tool compound in several experimental settings. In cell culture it is applied to endothelial cells, tendon-derived fibroblasts and gut epithelial cell lines to study migration, proliferation, tube formation and signalling responses. In wound-healing and scratch assays, it serves as a test article for comparing migration rates under defined conditions.
In animal research it features in models of tendon, ligament and muscle injury, gastrointestinal lesion models and vascular occlusion models, always under institutional ethical approval and the relevant national animal research legislation. In the UK, such work falls under the Animals (Scientific Procedures) Act 1986 where applicable. In analytical chemistry it is used as a reference peptide for method development, including reversed-phase HPLC and mass spectrometry workflows for proline-rich peptides, where its stability and distinct fragmentation pattern are useful.
All of these applications are strictly in-vitro or preclinical. Nothing in the literature supports extrapolation to human use, and none of the above should be read as a claim about benefit in people.
Purity, storage and handling
Because the safety record is thin, the quality of the material is a first-order variable in any experiment. High-performance liquid chromatography (HPLC) is the standard method for confirming peptide purity, and a figure of 98% or above is generally expected for research-grade BPC 157. HPLC alone does not confirm identity, so a credible certificate of analysis also includes mass spectrometry confirming the expected molecular weight of approximately 1419.5 Da. A certificate should be batch-specific and carry a batch number matching the vial, because a generic or recycled certificate says nothing about the lot actually received. Residual trifluoroacetic acid content, water content and, for cell work, endotoxin testing are additional parameters worth requesting.
Stability is a second consideration. Although the proline-rich sequence confers comparative resilience, the peptide is still a peptide, and degradation accelerates once it is in solution. Because degradation accelerates after reconstitution, batch-level HPLC verification matters more here than with more stable compounds. UK laboratories sourcing bpc 157 side effects research material or looking to buy best peptides for comparative studies should expect a batch-specific certificate of analysis and lyophilised storage at -20°C.
Lyophilised powder is typically stable for extended periods at -20°C when kept sealed, dry and protected from light, and short-term storage at 2 to 8°C is commonly tolerated for transit. Once reconstituted, usually in sterile or bacteriostatic water for laboratory purposes, solutions are generally kept at 2 to 8°C and used within a short window. Repeated freeze-thaw cycles should be avoided, so single-use aliquots are the usual practice. The peptide should be shielded from prolonged light exposure, and vials should be allowed to reach room temperature before opening to prevent moisture uptake. Standard laboratory personal protective equipment applies, and the compound should be handled in line with the institution’s chemical risk assessment.
Frequently asked questions
What are the known BPC 157 side effects?
No validated side effect profile exists. Preclinical studies in rodents rarely report adverse findings, but they were short, small and mostly produced by one research network. Human safety data is limited to a few small preliminary reports, so absence of reported effects should not be interpreted as demonstrated safety.
Is BPC 157 legal in the UK?
BPC 157 is not a licensed medicine in the UK and has no MHRA marketing authorisation. It can be supplied as a laboratory research chemical, but marketing or supplying it for human consumption is restricted under medicines legislation. It is also prohibited under the WADA list as a non-approved substance.
Has BPC 157 been tested in human clinical trials?
Only on a very limited scale. A few small pilot and retrospective reports exist, and an early phase I programme was reportedly started for a related formulation, but results were not comprehensively published. Large, registered, randomised controlled trials have not been completed, so the evidence base remains predominantly preclinical.
How should lyophilised BPC 157 be stored in the laboratory?
Lyophilised BPC 157 is generally stored sealed at -20°C, away from light and moisture. After reconstitution, solutions are usually kept at 2 to 8°C and used within a short period, with single-use aliquots preferred to avoid repeated freeze-thaw cycles. Storage should always follow the batch certificate and institutional protocols.
BPC 157 is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and nothing in this article should be read as guidance on administration, dosing or therapeutic benefit.